China's stimulus efforts have attracted a surge of Gen Z investors into the stock market, highlighting their growing risk appetite and investment strategies.
In 2025, Big Pharma plans to pursue acquisitions to replace lost revenue from expiring patents on major drugs, focusing on obesity and oncology markets.